Spring Bank Pharmaceuticals Inc

Spring Bank Pharmaceuticals — F-star Therapeutics — Q3 2021 Earnings Presentation

26 slides from Spring Bank Pharmaceuticals's earnings presentation, Aug 12, 2021

  1. Slide 1: Q3 2021 Next Generation Immunotherapies. Overcoming Cancer.

    Q3 2021 Next Generation Immunotherapies. Overcoming Cancer. Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These

  3. Slide 3: F-star at a Glance

    Developing next generation immunotherapies to transform the lives of patients with cancer F-star at a Glance Validating Partnerships Natural human format for better manufacturing and safety “Plug & Play” versatility for rapid drug discovery Rational drug design: Four binding sites with tuneable affi

  4. Slide 4: F-star's Potential to Deliver Investor Value

    Successful, experienced team with 20 approved drugs F-star’s Potential to Deliver Investor Value Cash runway through multiple clinical milestones Key Financial Highlights* $81.6M Cash 20.6M Common Shares Outstanding *as of 30th June 2021 Four 2nd generation IO therapeutics in the clinic Funded by to

  5. Slide 5: Experienced Management Team

    Experienced Management Team Medical oncologist with 25+ years' experience in clinical research in Europe and US Experience in registrational studies, registration strategy and drug approval Louis Kayitalire CMO, MD 25+ years leading financial operations in public and private companies Proven track r

  6. Slide 6: Four Differentiated Clinical Programs

    Four Differentiated Clinical Programs FS120 Improving CPI and chemotherapy outcomes CONDITIONAL OX40/CD137 (4-1BB) DUAL STIMULATOR Ongoing Phase 1 trial in solid tumors MSD clinical supply agreement in place for pembrolizumab Update on accelerated dose titration in H2 2021 FS118 Overcoming and preve

  7. Slide 7: Anticipated Future Data Milestones

    Update on dose escalation FS222 Update on accelerated dose titration FS120 Safety, biomarker and preliminary efficacy data FS222 Update dose escalation SB 11285 FS120 Safety & biomarker update & initiation of Keytrudaâ cohorts FS222 Safety update to support initiation of PK/PD expansion cohorts Anti

  8. Slide 8: FS118 Overcoming and preventing CPI-treatment failures

    FS118 Overcoming and preventing CPI-treatment failures LAG-3 PD-L1

  9. Slide 9: FS118: Profound Inhibition through LAG-3 Shedding

    FS118: potent dual antagonist which induces LAG-3 shedding CONFIDENTIAL FS118: Profound Inhibition through LAG-3 Shedding “Given the uncertainty over LAG-3 ligands and coverage of blocking epitopes, cleavage is one way to ensure antagonism of all LAG-3 – ligand interactions.” Analyst FS118 Different

  10. Slide 10: Building Opportunity - Expanding FS118 Clinical Strategy

    Building Opportunity - Expanding FS118 Clinical Strategy FS118 overcomes Acquired Resistance to PD-1 blockade by inducing LAG-3 shedding while inhibiting PD-L1 FS118 avoids resistance to PD-1 blockade by preventing LAG-3 upregulation while inhibiting PD-L1 Hypotheses CPI naïve Post PD-1 CPI-naïve, P

  11. Slide 11: FS118 Global Clinical Development Plan

    FS118 Global Clinical Development Plan Ph I: First in Human Well tolerated up to 20 mg/kg with RP2D of 10 mg/kg Clinical benefit observed in tumors co-expressing LAG-3/PD-L1 59% DCR in PD-(L)1 acquired resistant patients Potent novel anti-LAG-3 mechanism leading to prolonged increased levels of solu

  12. Slide 12: FS222 Improving outcomes in PD-L1 low tumors

    CD137 PD-L1 FS222 Improving outcomes in PD-L1 low tumors

  13. Slide 13: FS222 outperforms other bispecifics in primary immune cell assays

    FS222 outperforms other bispecifics in multiple human primary immune cell assays Ref: Lakins et al, FS222, a Tetravalent Bispecific Antibody Targeting CD137 and PD-L1, is Designed for Optimal CD137 Interactions Resulting in Potent T cell Activation Without Toxicity, AACR 2021 Tetravalent bispecific

  14. Slide 14: FS222 Phase Study Design: Seamless & Adaptive

    FS222 Phase 1 Study Design: Seamless & Adaptive PART B Update H1 2022 Cohort expansion Planned PART A Update late 2021 Dose escalation & PK/PD expansion Confidence to proceed to indication specific expansion n = ~50 On-going Safety, PK/PD, Biomarkers n = 25+ Colorectal n = 25+ Ovarian n = 25+ NSCLC

  15. Slide 15: FS120 Improving CPI and chemotherapy outcomes

    OX40 CD137 FS120 Improving CPI and chemotherapy outcomes

  16. Slide 16: FS120 Has a Differentiated Mechanism with Broad Potential For Combination

    CONFIDENTIAL FS120 Has a Differentiated Mechanism with Broad Potential For Combination Improving anti-tumor immune response by “Triple Activation”*: Activates CD8+ and NK effector cells Increases CD4+ cell helper activity Destabilizes Tregs FS120 + anti-PD-1 combination FS120 + chemotherapy combinat

  17. Slide 17: FS120: Phase 1 Study Design

    PART B Initiate 2022 PART A Update Q3 2021 PART C FS120: Phase 1 Study Design Monotherapy dose escalation On-going PD-1 combo dosing frequency and dose escalation Planned Planned Combination dose expansion Determination of pharmacologically active dose n = 40+ n = ~30 n = 25+ n = 25+ n = 25+ NSCLC (

  18. Slide 18: STING agonist SB 11285 Improving CPI outcomes

    STING agonist SB 11285 Improving CPI outcomes

  19. Slide 19: SB 11285 Phase Study Design

    SB 11285 Phase 1 Study Design PART 1a SB 11285 appears well tolerated alone and with atezolizumab across all dose levels Heavily pre-treated tumors with some evidence of disease control PK profile aligns with likely immune cell uptake Biomarker data encourages further dose escalation PART 1b Continu

  20. Slide 20: Anticipated Future Data Milestones

    Update on dose escalation FS222 Update on accelerated dose titration FS120 Safety, biomarker and preliminary efficacy data FS222 Update dose escalation SB 11285 FS120 Safety & biomarker update & initiation of Keytrudaâ cohorts FS222 Safety update to support initiation of PK/PD expansion cohorts Anti

  21. Slide 21: FSTX – A Stellar Outlook

    CONFIDENTIAL FSTX – A Stellar Outlook Four ongoing programs with multiple clinical data readouts in next 24 months Continued validation of platform & pipeline through big pharma alliances Strong balance sheet and support from top-tier biotech investors © 2020 F-star. All rights reserved

  22. Slide 22: F-star Potential Next Generation Immunotherapies

    CONFIDENTIAL F-star Potential Next Generation Immunotherapies

  23. Slide 23: Therapeutics - Thank you

    THERAPEUTICS Thank you.

  24. Slide 24: References

    Platform: Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments. DOI: 10.1093/protein/gzx042 Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics. DOI:10.1016/j.ymeth.2018.09.003. Bispecific antibodies: a m

  25. Slide 25: Bispecific Differentiation Through Crosslinking, Clustering and Conditionality

    Bispecific Differentiation Through Crosslinking, Clustering and Conditionality F-star mAb2 Traditional Antibody Antibody Combination Heterodimeric Bispecific Antibody Alternative Scaffold Bispecific Fragment Bispecific incl BITEs Bispecific crosslinking Conditional activity Tetravalent clustering Ig

  26. Slide 26: FS118: Lead LAG-3 x PD-L1 Bispecific

    CONFIDENTIAL FS118: Lead LAG-3 x PD-L1 Bispecific Format LAG-3 asset Company Anti-PD-(L)1 combination Lead indications Most Advanced Phase LAG-3 x PD-(L)1 FS118 (LAG-3 x PD-L1) F-star (FSTX) - SCCHN CPI naïve Ph 2 Tebotelimab (LAG-3 x PD-1) MacroGenics - Gastric Cancer, Gastroesophageal Junction Can

F-star Therapeutics — Q3 2021 Earnings Presentation on 6ix